RxDoctor Payments Data

Maryana Liedke, DO

Neurology · Port Jefferson Station, NYNPI 1386987956

Payments from drug & device makers

$181,772in general payments, 2019–2025

Across 1,179 payments — averaging $154.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$68K
  • Biogen$50K
  • TG Therapeutics, Inc.$25K
  • EMD Serono, Inc.$13K
  • Genentech USA, Inc.$7K
  • AbbVie$4K
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$21,20118%
  • Speaking & faculty fees$57,62550%
  • Travel & lodging$7,9017%
  • Food & beverage$27,58124%
  • Education$3480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis67$68,416
Biogen206$50,480
TG Therapeutics, Inc.38$25,406
EMD Serono, Inc.59$12,992
Genentech USA, Inc.55$6,941
AbbVie(2 entities)251$4,319
Amgen(2 entities)65$1,816
Sanofi35$1,060
UCB, Inc.31$735
Biohaven Pharmaceuticals, Inc.14$720
Lundbeck LLC35$685
Harmony Biosciences LLC26$673
Argenx US, Inc.23$626
SK Life Science, Inc.11$505
AstraZeneca(2 entities)20$496
Takeda Pharmaceuticals U.S.A., Inc.15$454
Bristol Myers Squibb19$433
E.r. Squibb & Sons, L.L.C.7$414
Amneal Pharmaceuticals LLC18$411
Lilly USA, LLC16$343
Biohaven Pharmaceutical Holding Company Ltd.9$325
Scilex Pharmaceuticals Inc.15$285
Acorda Therapeutics, Inc14$239
Pfizer11$218
Neurocrine Biosciences, Inc.8$214
Supernus Pharmaceuticals, Inc.12$198
Johnson & Johnson(2 entities)4$179
Upsher-smith Laboratories LLC9$163
Jazz Pharmaceuticals Inc.8$155
Teva Pharmaceuticals USA, Inc.3$149
Janssen Scientific Affairs, LLC1$127
CSL Behring1$116
Axsome Therapeutics, Inc.4$105
Merz Pharmaceuticals, LLC4$99
Vanda Pharmaceuticals Inc.5$95
Otsuka America Pharmaceutical, Inc.4$93
Currax Pharmaceuticals LLC5$82
Grifols USA, LLC3$81
Almatica Pharma LLC3$67
Inspire Medical Systems, Inc.2$61
Arbor Pharmaceuticals, Inc.4$58
ANI Pharmaceuticals, Inc.2$53
Tonix Medicines, Inc.3$53
Assertio Therapeutics, Inc.3$51
Medtronic2$50
Acadia Pharmaceuticals Inc3$47
Protega Pharmaceutials Inc3$43
Vertex2$42
Tanabe Pharma America, Inc.2$39
Catalyst Pharmaceuticals, Inc.1$38
Neuronetics, Inc.1$32
Bausch Health US, LLC2$30
Microtransponder, Inc.1$25
Mallinckrodt Hospital Products Inc.1$22
Averitas Pharma Inc.1$20
Avanir Pharmaceuticals, Inc.1$19
Banner Life Sciences, LLC1$18
Merck1$18
Ipsen Biopharmaceuticals, Inc1$18
Collegium Pharmaceutical, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$181,772 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$81,712
Medicare patients
254
Services billed
2,942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab31$293,524
VumerityDiroximel Fumarate21$167,059
MayzentSiponimod13$126,959
TysabriNatalizumab13$121,039
Teriflunomide19$72,049
FingolimodFingolimod Hcl11$18,434
TopamaxTopiramate24$16,223
QuliptaAtogepant12$14,769
Nurtec OdtRimegepant Sulfate11$10,453
Dalfampridine ErDalfampridine22$10,366
Pregabalin59$2,233
Baclofen62$1,707
Gabapentin135$1,343
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine35$801
Memantine Hcl36$691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Tysabri$50,480$288,09834 claims
NovartisMayzent$68,416$126,95913 claims
AbbVieQulipta$4,319$14,76912 claims
PfizerNurtec Odt$218$10,45311 claims
Upsher-smith Laboratories LLCTopiramate$163$7714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Port Jefferson Station

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →